The University of Dublin | Trinity College -- Ollscoil Átha Cliath | Coláiste na Tríonóide
Trinity's Access to Research Archive
Home :: Log In :: Submit :: Alerts ::

TARA >
School of Medicine >
Pharmacology & Therapeutics >
Pharmacology & Therapeutics (Scholarly Publications) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2262/56910

Title: Interaction between prion protein and toxic amyloid ß assemblies can be therapeutically targeted at multiple sites.
Author: ROWAN, MICHAEL JOSEPH
KLYUBIN, IGOR
Sponsor: 
Name Grant Number
RP/2008/30
08/1N.1/B2033
06/IN.1/B88

Author's Homepage: http://people.tcd.ie/mrowan
http://people.tcd.ie/klyubini
Keywords: Neuroscience
Alzheimer's disease (AD)
Issue Date: 2011
Publisher: Nature
Citation: Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J, Interaction between prion protein and toxic amyloid ß assemblies can be therapeutically targeted at multiple sites., Nature Communications, 2, 336, 2011
Series/Report no.: Nature Communications;
2;
336;
Abstract: A role for PrP in the toxic effect of oligomeric forms of Aβ, implicated in Alzheimer's disease (AD), has been suggested but remains controversial. Here we show that PrP is required for the plasticity-impairing effects of ex vivo material from human AD brain and that standardized Aβ-derived diffusible ligand (ADDL) preparations disrupt hippocampal synaptic plasticity in a PrP-dependent manner. We screened a panel of anti-PrP antibodies for their ability to disrupt the ADDL–PrP interaction. Antibodies directed to the principal PrP/Aβ-binding site and to PrP helix-1, were able to block Aβ binding to PrP suggesting that the toxic Aβ species are of relatively high molecular mass and/or may bind multiple PrP molecules. Two representative and extensively characterized monoclonal antibodies directed to these regions, ICSM-35 and ICSM-18, were shown to block the Aβ-mediated disruption of synaptic plasticity validating these antibodies as candidate therapeutics for AD either individually or in combination.
Description: PUBLISHED
URI: http://hdl.handle.net/2262/56910
Related links: http://dx.doi.org/10.1038/ncomms1341
Appears in Collections:Pharmacology & Therapeutics (Scholarly Publications)

Files in This Item:

File Description SizeFormat
Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites.pdfPublished (publisher's copy) - Peer Reviewed977.88 kBAdobe PDFView/Open


This item is protected by original copyright


Please note: There is a known bug in some browsers that causes an error when a user tries to view large pdf file within the browser window. If you receive the message "The file is damaged and could not be repaired", please try one of the solutions linked below based on the browser you are using.

Items in TARA are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback